Current Research Studies
The following are ongoing clinical research studies being conducted at the MRC or at affiliated sites by MRC investigators. If you would like to participate in one of our research studies, please e-mail email@example.com and indicate which study you are interested in.
This follow-up to the MESA study seeks to compare the effects of sugar-sweetened beverages vs. naturally sweetened beverages (orange juice) in healthy individuals.
The aim of the RIOT trial is to determine whether osteopathic manipulative treatment (OMT) will blunt changes in serum cytokines that are markers of inflammation and adipokines in asymptomatic subjects.
Sanofi LixiLan-D Study
This 26-week study compares the efficacy and safety of Soliqua 100/33 vs. Lantus in ethnically/racially diverse patients with Type 2 diabetes inadequately controlled on basal insulin and oral antidiabetic agents. Eligible individuals include Hispanics, non-Hispanic African Americans, or non-Hispanic Asians with type 2 diabetes and taking basal insulin and oral antidiabetic medications with HbA1c between 7.5%-10%.
Eli Lilly AWARD-PEDS
This Phase III trial tests if the drug, dulaglutide, is effective and safe for treating type 2 diabetes in children and teens.
Recently Completed Studies:
Cardiovascular Inflammation Reduction Trial (CIRT)
The primary aim of the Cardiovascular Inflammation Reduction Trial (CiRT) is to directly test the inflammatory hypothesis of atherothrombosis by evaluating whether or not low-dose methotrexate will reduce rates of myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.
Takeda Phase 3 Alogliptin Pediatric Study
The purpose of this study is to evaluate the efficacy and safety of alogliptin when administered as a monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, in 10-17 year olds with type 2 diabetes mellitus.
Copyright 2005 - 2017, Touro University, All Rights Reserved.